IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Lipocine Inc. And Reminds
Investors With Losses To Contact The Firm
Lundin Law PC announces a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company") (Nasdaq: LPCN)
concerning possible violations of federal securities laws between June 30, 2015 and June 28, 2016 (the “Class Period”). Investors
who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 30, 2016
lead plaintiff motion deadline.
To participate in this class action lawsuit, click here to participate. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail
him at brian@lundinlawpc.com.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney.
You may also choose to do nothing and be an absent class member.
According to the complaint, during the Class Period the Company made false and/or misleading statements and/or failed to
disclose that: Lipocine’s filing of its New Drug Application to the U.S. Food and Drug Administration for LPCN 1021 (the Company’s
lead product candidate) contained deficiencies; and as a result, Lipocine’s statements about its business and operations were false
and misleading and/or lacked a reasonable basis. When this information entered the market, investors suffered losses.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/
View source version on businesswire.com: http://www.businesswire.com/news/home/20160705006004/en/